Why the study?
Since the 2012 ACCP guidelines, improved understanding of VTE diagnosis and prognosis and the introduction of NOACs have changed treatment options for VTE.
This guideline update incorporates NOACs into the treatment landscape for VTE and provides specific recommendations for subsegmental PE and cancer-associated VTE.
The estimated annual incidence of VTE, defined as DVT of the leg or PE, ranges from 104 to 183 per 100 000 person-years.1 Compared with those without VTE, the 30-year mortality risk is increased for survivors of an episode of VTE and for survivors of an episode of PE (64 vs 136 and 211 per 1000 person-years, respectively).2 In 2012, the ACCP released the ninth-edition guidelines for antithrombotic therapy and prevention of thrombosis.3 Since the publication of that guideline, there has been improved understanding of the diagnosis and prognosis of VTE. The addition of non–vitamin K oral anticoagulants (NOACs) has altered the landscape of treatment options. This update addresses the role for NOACs and provides new recommendations for management of subsegmental PE and treatment of cancer-associated VTE.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2017) conducted a review in Venous Thromboembolic Disease. Non-vitamin K oral anticoagulants (NOACs) was evaluated. This guideline update provides new recommendations for the use of non-vitamin K oral anticoagulants in the management of subsegmental pulmonary embolism and cancer-associated venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: